The invention is applicable to recombinant proteins bound to an antigenic peptide in diagnosis or therapy.
The HSP may be uncomplexed to an antigenic peptide.
The present invention provides improved vaccines comprising an isolated viral antigenic peptide and a synthetic peptide derived from a T cell epitope of HSP60.
We identified the gene encoding the antigenic peptide recognised by a HB-1 specific CTL.
The cells may also be exposed to a CD28 stimulatory binding agent, either alone or in combination with the antigenic peptide.
If the target protein or peptide is an antigen protein or an antigen peptide, the transformed Bifidobacterium is useful as an oral vaccine.
Provided is an antigen peptide used for detecting anti-human papilloma virus (HPV) antibodies, said antigen peptide being derived from the HPV E7 protein.
The invention relates to antigen peptide derived from the Nectin4 and its use for preventing and treating cancer.
The present invention relates to: an antigen peptide originated from a T790M point-mutated sequence of an EGFR; and a medicinal agent for treating cancer, which comprises the peptide.
In the virus vector according to the present invention, the antigen peptide is contained on a virus particle in a quantitatively large amount.
The complexes present the antigenic peptide to a T cell or an antigen presenting cell (APC) which mounts the immune response.
Each of the antigen polypeptides is a wild-type antigen protein of Plasmodium or a derivative of the wild-type antigen protein, and each of the antigen polypeptides may be the same, or different.
The present invention addresses the problem of providing a transdermal preparation which enables the more efficient induction of a CTL by a cancer antigen peptide derived from WT1 protein.
Generally, the vaccine includes an expression vector that encodes a clinically relevant breast cancer-associated antigenic peptide and an IRM compound.
Further provided by this invention is an antibody directed to an epitope on the Ri paraneoplastic antigenic polypeptide.
This invention also provides a purified Ri antigenic polypeptide and compositions containing the purified Ri antigenic polypeptide.
The invention is additionally directed to formulations comprising an antigenic peptide joined by a linker to an MHC segment anchored in a lipid-containing substrate.
In one aspect, an effective amount of an antigenic peptide binding protein (APBP) and a cytotoxic agent are administered to the subject.
The method of the present invention comprises contacting a population of cells with an MHC restricted antigenic peptide, a cytokine and a co-stimulatory signal.
More preferably, the antibody binds to HLA-DR and the antigenic peptide is from an immunomodulating factor, such as the viral IL-18 binding protein (vIL18BP).
Requêtes fréquentes français :1-200, -1k, -2k, -3k, -4k, -5k, -7k, -10k, -20k, -40k, -100k, -200k, -500k, -1000k,
Requêtes fréquentes anglais :1-200, -1k, -2k, -3k, -4k, -5k, -7k, -10k, -20k, -40k, -100k, -200k, -500k, -1000k,
Traduction Translation Traducción Übersetzung Tradução Traduzione Traducere Vertaling Tłumaczenie Mετάφραση Oversættelse Översättning Käännös Aistriúchán Traduzzjoni Prevajanje Vertimas Tõlge Preklad Fordítás Tulkojumi Превод Překlad Prijevod 翻訳 번역 翻译 Перевод